Summary by Moomoo AI
SciSparc Ltd., a clinical-stage pharmaceutical company, announced the successful dosing of the first patient in its SCI-210 clinical trial for Autism Spectrum Disorder (ASD) on March 14, 2024. The trial is being conducted at the Soroka Medical Center and targets pediatric patients. This marks a significant advancement following the company's recent update on the delivery of its SCI-210 treatment to the clinical site. The treatment comprises a combination of cannabidiol-rich oil and CannAmide, SciSparc's proprietary palmitoylethanolamide-based tablets. The study is designed as a randomized, double-blind, placebo-controlled trial with cross-over, set to last 20 weeks and enroll 60 children. It aims to assess the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. The primary efficacy...Show More